The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...
Management reiterated no specific revenue or earnings guidance would be provided. Kelley expressed continued optimism, stating, "our current backlog places us in a strong position going into the ...
Q4 2025 earnings call recap: record revenue, expanded key customer contract, and 2026 EBITDA guidance of $20–$22M—read now.
CHICAGO, IL, UNITED STATES, January 21, 2026 /EINPresswire.com/ — Europe’s contract catering market is entering a phase where growth is being redistributed rather ...
Hosted on MSN
AdaptHealth outlines 6%–8% revenue growth target for 2026 as new capitated contracts ramp
Clemens said, “We are maintaining our full year 2025 revenue guidance range and expect to come in very modestly above the midpoint of that range. We are also maintaining our full year 2025 adjusted ...
Carrie Lachance, President, CEO & Director, reported "solid top line growth of 7% with full year adjusted EBITDA expanding 24% to $31.5 million and strong operating cash flow of $7.1 million." ...
BlackSky Technology BKSY continues to attract attention in the space and defense technology sector, with one factor front and center: contract momentum with government clients. The company’s real-time ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results